Moderna founder launches new biotech, looking to cure diseases through 'endless RNA'

Bio Pharma Dive

Laronde comes equipped with $50 million in funding from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines

RNA 272

Eli Lilly Pursues RNA Editing in New Partnership with ProQR

XTalks

billion deal will see the companies use ProQR’s proprietary Axiomer RNA editing platform technology to advance editing oligonucleotide-based therapeutics toward clinical development and commercialization.

RNA 84
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

As Arrowhead falters, lungs remain a tough target for RNA drugs

Bio Pharma Dive

The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs

RNA 231

Venture capital pours more money into RNA medicines with the launch of Replicate

Bio Pharma Dive

The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen

RNA 211

Moderna founder's next big play in RNA raises $440 million

Bio Pharma Dive

Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus

RNA 270

Lilly joins RNA editing race with ProQR deal

Bio Pharma Dive

An agreement with the Dutch biotech, which could be worth as much as $1.3 billion, expands Lilly's work in genetic medicine research

RNA 211

Roche adds to RNA drug deal streak with Ribometrix partnership

Bio Pharma Dive

The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules

RNA 146

RNA Therapeutics Experience Renaissance Amidst Global Pandemic

BioSpace

RNA caught the public’s imagination in the form of mRNA vaccines against COVID-19, but RNA can be used in other ways, too, to make therapeutic proteins

RNA 83

RNA modification may protect against liver disease

Scienmag

RNA 83

Regulating the ribosomal RNA production line

Scienmag

coli enzyme synthesizing ribosomal RNA that shift it between turbo- and slow-modes depending on the bacteria’s growth rate Credit: Murakami Laboratory, Penn State The enzyme that makes RNA from a DNA template is altered to slow the production of ribosomal RNA (rRNA), the […].

RNA 83

Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal

Pharma Phorum

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . News R&D Eli Lilly MiNA Therapeutics partnering rna RNA-based drugs

RNA 68

Biogen taps Envisagenics’ AI to speed up RNA splicing R&D

Pharma Phorum

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. Cambridge, Massachusetts-based Envisagenics focuses on using AI to analyse errors in RNA splicing, a process in which a precursor form of messenger RNA (mRNA) – which is used as a template for protein synthesis in cells – is transformed into a mature form.

RNA 53

‘Endless RNA’ startup Laronde raises $440m to fuel pipeline

Pharma Phorum

Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. News R&D Flagship Pioneering Laronde Moderna rna

RNA 52

2nd RNA Editing Summit 2020

Pharma Phorum

The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible. The post 2nd RNA Editing Summit 2020 appeared first on.

RNA 52

#news #biotech Sequencing multiple RNA base modifications simultaneously: A new era of RNA biology

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sequencing multiple RNA base modifications simultaneously: A new era of RNA biology.After a gene is transcribed into RNA, modifications can occur to the subunits or “bases” that … Continue reading → #news

RNA 40

RNA holds the reins in bacteria: U-M researchers observe RNA controlling protein synthesis

Scienmag

Credit: Surajit Chatterjee To better understand how RNA in bacteria gives rise to protein–and along the way, target these processes in the design of new antibiotics–researchers are turning their attention to the unique way this process happens in bacteria.

RNA 83

Oncotarget: Urine RNA reveal tumor markers for human bladder cancer

Scienmag

Oncotarget published “Transcriptome analyses of urine RNA reveal tumor markers for human bladder cancer: validated amplicons for RT-qPCR-based detection” which reported that in case of bladder cancer, […].

RNA 82

3rd RNA-Targeted Drug Discovery Summit

Pharma Phorum

The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. Why You Should Attend the RNA- Targeted Drug Discovery Summit.

RNA 52

Endless RNA Creator Secures $440 Million to Build Gigabase Factory

BioSpace

?Laronde has managed to secure as much as $440 million from a Series B financing round to support as many as 100 Endless RNA (eRNA) products and drug programs over the next decade

RNA 83

Parse Biosciences Extends RNA-Seq Kit Reach to Australia and New Zealand through Decode Sciences Agreement

BioTech 365

RNA 52

RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics – ResearchAndMarkets.com

BioTech 365

RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics – ResearchAndMarkets.com RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

RNA 40

Scientists behind RNA-repairing strategy recognized with American Chemical Society’s Nobel Signature award

Scienmag

Biogen, Ionis tout data from early study of RNA-based Alzheimer's drug

Bio Pharma Dive

The companies said that patients treated with their experimental drug BIIB080 had reductions in a protein called tau, which research indicates is tied to Alzheimer's but isn't yet proven to impact the course of the disease

RNA 149

RNA Editor ProQR Lines Up $1.5 Billion Deal with Eli Lilly

BioSpace

?The partnership combines the companies' resources to focus on Axiomer, a technology that can edit single nucleotides in RNA in a specific and highly targeted manner

RNA 83

4th RNA-Targeted Drug Discovery Summit – Digital Event

Pharma Phorum

Key Highlights: Expand your knowledge of the RNA landscape by gaining exclusive insights and data-driven updates to streamline the success of your RNA candidates from leaders of the field such as Nymirum, Arrakis, PTC Bio & Expansion Therapeutics.

RNA 52

HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India

BioTech 365

HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India Vaccine Would Be India’s First Indigenous RNA Vaccine, Exemplifying HDT … Continue reading → Business Wire

RNA 52

Study identifies noncoding RNA involved in immune response and sepsis

Scienmag

NSF backs bioinformatics approach to understanding plant RNA modifications

Scienmag

Led by Boyce Thompson Institute’s Andrew Nelson, four partners will identify RNA modifications and develop resources that may lead to hardier crops Credit: Photo credit: Anna Nelson Dittrich ITHACA, NY, August 4, 2020 — RNA perform a variety of functions in cells, helping with everything from regulating genes to building proteins.

Skyhawk and Vertex Team Up on RNA Splicing-Based Therapies

BioSpace

Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing

MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD

BioTech 365

MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD CAMBRIDGE, Mass.–(BUSINESS

RNA 52

Locanabio’s RNA-Targeting Gene Therapy May Offer Durable Response for DM1 Patients

BioSpace

RNA-binding proteins are emerging as the next generation of molecular medicine

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast

Pharma Phorum

With RNA-based technology hitting the headlines in recent months due to its use in Covid vaccines, he also discusses the version of it that Galapagos uses and how it can produce compounds that might alter the course of a disease.

RNA 52

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

BioTech 365

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA … Continue reading → Business Wire

RNA 52

Ribometrix and Genentech Partner in Potential $1 Billion+ RNA Deal

BioSpace

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech to identify and advance novel RNA-targeted small molecule therapeutics

RNA 83

Potential drug target for difficult-to-treat breast cancer: RNA-binding proteins

Scienmag

RNA 83

Comparing symptoms, RNA levels in patients with SARS-CoV-2 infection

Scienmag

What The Study Did: Researchers compared the association between symptoms and SARS-CoV-2 RNA levels in children and adults. Authors: Erin Chung, M.D., of the University of Washington School of Medicine in Seattle, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link [link] (doi:10.1001/jamapediatrics.2021.2025) Editor’s Note: The […].

RNA 60

#news #biotech RNA-targeting enzyme expands the CRISPR toolkit

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: RNA-targeting enzyme expands the CRISPR toolkit.Researchers at MIT’s McGovern Institute for Brain Research have discovered a bacterial enzyme that they say could expand scientists’ CRISPR toolkit, making … Continue reading → #news

RNA 40

Locanabio Raises $100 Million to Advance RNA-Targeted Gene Therapies

BioSpace

San Diego-based Locanabio secured $100 million in a Series B financing round that will be used to advance the company’s portfolio of novel RNA-targeted gene therapies for neurodegenerative, neuromuscular and retinal diseases

Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

BioTech 365

Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease Oversubscribed round enables late-stage clinical development of lead … Continue reading → Business Wire

RNA 52

Chemical modification of RNA could play key role in polycystic kidney disease

Scienmag

RNA 82

Deep Genomics is Rewriting RNA for Powerful Therapeutics with $180M Series C

BioSpace

That's the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey "For the first time in history, medicine has become information."

RNA 83

16S Ribosomal RNA (16S rRNA) Drugs in Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com

BioTech 365

16S Ribosomal RNA (16S rRNA) Drugs in Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com 16S Ribosomal RNA (16S rRNA) Drugs in Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “16S Ribosomal RNA (16S rRNA) – Drugs in Development, 2021” … Continue reading → Business Wire

RNA 40

Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com

BioTech 365

Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Growth Opportunities in RNA … Continue reading → Business Wire

RNA 40